Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions for surgical fixation of bone fractures for upper and lower extremities, as well as for the craniomaxillofacial region.
The last earnings update was 86 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Medartis Holding. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Medartis Holding's earnings available for a low price, and how does
this compare to other companies in the same industry?
Medartis Holding's earnings are expected to grow significantly at over 20% yearly.
Medartis Holding's revenue is expected to grow by 17.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Medartis Holding's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Medartis Holding's finances.
The net worth of a company is the difference between its assets and liabilities.
Medartis Holding is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Medartis Holding's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Medartis Holding's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 71.2x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Christoph Brönnimann has been Chief Executive Officer and Member of Executive Management Board of Medartis Holding AG since September 1, 2019 and has responsibility for the sales organisation since November 1, 2019. Mr. Brönnimann has a successful international track record in medical technology management positions. In 2005, he joined Synthes, where he was responsible for the global integration of Stratec and Mathys and held various leadership roles in larger organizational units. Among other things, he was responsible for global quality management and new product approvals and oversaw international logistics. He later became General Manager of Synthes Switzerland. At Johnson & Johnson, following its acquisition of Synthes, he was first responsible for DePuySynthes Germany and then headed the J&J ONE Medical Device unit for Germany, Switzerland and Austria as a Member of the Medical Devices Europe Executive Board. Prior to his time at J&J and Synthes, his roles included working at PwC in M&A consulting and corporate finance. He began his career at Roche, where he worked in marketing and product management in the US from 1996 to 2000. He has a PhD in chemistry from ETH Zurich and completed a General Management Program at Harvard Business School.
Insufficient data for Christoph to compare compensation growth.
Insufficient data for Christoph to establish whether their remuneration is reasonable compared to companies of similar size in Switzerland.
Management Team Tenure
Average tenure and age of the
management team in years:
The average tenure for the Medartis Holding management team is over 5 years, this suggests they are a seasoned and experienced team.
CEO & Member of Executive Management Board
CFO, Deputy CEO & Member of Executive Management Board
Chief Production Officer & Member of Executive Management Board
CTO & Member of Executive Management Board
Chief Human Resources Officer & Member of the Executive Management Board
Head of Corporate Services
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Medartis Holding board of directors is about average.
Board of Directors
H. C. Straumann
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
These 4 Measures Indicate That Medartis Holding (VTX:MED) Is Using Debt Reasonably Well
SWX:MED Historical Debt, September 2nd 2019 How Strong Is Medartis Holding's Balance Sheet? … While Medartis Holding has net cash on its balance sheet, it's still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. … Summing up While we empathize with investors who find debt concerning, you should keep in mind that Medartis Holding has net cash of CHF116.3m, as well as more liquid assets than liabilities.
Could The Medartis Holding AG (VTX:MED) Ownership Structure Tell Us Something Useful?
Check out our latest analysis for Medartis Holding SWX:MED Ownership Summary, August 15th 2019 What Does The Institutional Ownership Tell Us About Medartis Holding? … We can see that Medartis Holding does have institutional investors; and they hold 14% of the stock. … Insider Ownership Of Medartis Holding While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.
Those Who Purchased Medartis Holding (VTX:MED) Shares A Year Ago Have A 19% Loss To Show For It
Unfortunately the Medartis Holding AG (VTX:MED) share price slid 19% over twelve months. … Medartis Holding may have better days ahead, of course; we've only looked at a one year period. … During the last year Medartis Holding grew its earnings per share, moving from a loss to a profit.
Should Medartis Holding AG (VTX:MED) Focus On Improving This Fundamental Metric?
The formula for return on equity is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Medartis Holding: 1.9% = CHF4.2m ÷ CHF218m (Based on the trailing twelve months to December 2018.) It's easy to understand the 'net profit' part of that equation, but 'shareholders' equity' requires further explanation. … How Does Debt Impact Return On Equity? … Medartis Holding's Debt And Its 1.9% ROE Although Medartis Holding does use a little debt, its debt to equity ratio of just 0.015 is very low.
Examining Medartis Holding AG’s (VTX:MED) Weak Return On Capital Employed
Analysts use this formula to calculate return on capital employed: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) Or for Medartis Holding: 0.026 = CHF6.1m ÷ (CHF256m - CHF20m) (Based on the trailing twelve months to December 2018.) So, Medartis Holding has an ROCE of 2.6%. … Due to the way ROCE is calculated, a high level of current liabilities makes a company look as though it has less capital employed, and thus can (sometimes unfairly) boost the ROCE. … Medartis Holding has a low level of current liabilities, which have a negligible impact on its already low ROCE.
What Kind Of Shareholder Appears On The Medartis Holding AG's (VTX:MED) Shareholder Register?
A look at the shareholders of Medartis Holding AG (VTX:MED) can tell us which group is most powerful. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … With a market capitalization of CHF656m, Medartis Holding is a small cap stock, so it might not be well known by many institutional investors.
Did Changing Sentiment Drive Medartis Holding's (VTX:MED) Share Price Down By 16%?
Unfortunately the Medartis Holding AG (VTX:MED) share price slid 16% over twelve months. … By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … During the last year Medartis Holding saw its earnings per share drop below zero.
Is Medartis Holding AG (VTX:MED) Worth CHF55.40 Based On Intrinsic Value?
Today, I will calculate the stock's intrinsic value. … by projecting its future cash flows and then discounting them to today's value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model
Do Insiders Own Shares In Medartis Holding AG (VTX:MED)?
The big shareholder groups in Medartis Holding AG (VTX:MED) have power over the company. … With a market capitalization of CHF816m, Medartis Holding is a decent size, so it is probably on the radar of institutional investors. … View our latest analysis for Medartis Holding
Is Medartis Holding AG's (SWX:MED) Stock Available For A Good Price After Accounting For Growth?
Medartis Holding AG (SWX:MED) is considered a high growth stock. … However its last closing price of CHF61.4 left investors wondering whether this growth has already been factored into the share price. … Medartis Holding's extremely high growth potential in the near future is attracting investors
Medartis Holding AG, a medical device company, develops, manufactures, and sells implant solutions for surgical fixation of bone fractures for upper and lower extremities, as well as for the craniomaxillofacial region. The company offers plates and screws solutions to treat various fractures, osteotomies, and degenerative diseases of hand, wrist, elbow, shoulder, and foot and ankle under the APTUS name; and implants for fracture fixations and osteotomies in the mandibular, and midface and cranial regions under the MODUS name. Medartis Holding AG’s products also used in tumor reconstruction and orthognathic deformities of the skull. The company sells its products through a network of direct sales representatives primarily to surgeons, hospitals, and medical centers, as well as to group purchasing organizations worldwide. Medartis Holding AG was founded in 1997 and is headquartered in Basel, Switzerland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.